Identification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray

Wenhua Jiang1,2, Pengfei Liu3, Xiaodong Li2

  • 1Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Sino-US Center of Lymphoma and Leukemia, Tianjin 300060, P.R. China.

Oncology Letters
|April 30, 2017
PubMed

Insights

This study identified key genes and signaling pathways, including the MAPK pathway, targeted by cediranib in alveolar soft part sarcoma (ASPS). Findings may guide future cediranib efficacy studies and new therapeutic target development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Alveolar soft part sarcoma (ASPS) is a rare cancer.
  • Cediranib is a targeted therapy with potential applications in ASPS.
  • Understanding cediranib's molecular targets in ASPS is crucial for optimizing treatment.

Purpose of the Study:

  • To identify cediranib's target genes in ASPS.
  • To elucidate the associated signaling pathways affected by cediranib in ASPS.
  • To provide insights for developing novel therapeutic strategies for ASPS.

Main Methods:

  • Utilized a microarray dataset (GSE32569) for gene expression analysis.
  • Employed R software for data normalization and differential gene expression analysis.
  • Performed Gene Ontology, Gene Set Enrichment Analysis, and constructed a protein-protein interaction network.

Main Results:

  • Identified 71 differentially expressed genes (DEGs) in ASPS, with 59 upregulated and 12 downregulated.
  • Discovered enrichment in four key signaling pathways: phenylalanine metabolism, mitogen-activated protein kinase (MAPK), taste transduction, and immunoglobulin A production.
  • Identified 107 transcription factors enriched in the MAPK signaling pathway and several potential cediranib target genes within the protein-protein interaction network.

Conclusions:

  • Cediranib targets specific genes and pathways in ASPS, notably the MAPK signaling pathway.
  • The identified targets and pathways offer potential for understanding cediranib's efficacy.
  • This research may facilitate the development of new therapeutic targets for ASPS treatment.